Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofirnoflast and Semaglutide in Obese Participants with Type 2 Diabetes
NCT07172867Phase 2Withdrawn
- Sponsor
- Halia Therapeutics
- Start
- Jan 2026
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
A Phase 2 trial of ofirnoflast in type 2 diabetes mellitus (T2DM), sponsored by Halia Therapeutics. Planned start Jan 2026; status: withdrawn.
02
Drugs
ofirnoflast
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07172867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172867.